Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics kicks off SURPASS clinical trial to target solid tumor cancers

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) CEO James Noble and Co-Founder Helen Tayton-Martin tell Proactive Investors the US and UK-based cell therapy company is kicking off its SURPASS clinical trial with its SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform, that allows T-cells to target and destroy solid tumor cancers.

Noble and Tayton-Martin say the SURPASS trial will now begin enrolling up to 30 patients across multiple solid tumor indications in the US, hoping to complete enrollment at year end.

Quick facts: Adaptimmune Therapeutics PLC

Price: $1.63

Market: NASDAQ
Market Cap: $171.36 m


e-Therapeutics’ Barlow hails deals with Novo Nordisk and ‘top five pharma...

Ray Barlow, chief executive of e-Therapeutics (LON:ETX), talks to Proactive’s Andrew Scott about the company’s unique approach to drug discovery, which uses computational techniques to find potential breakthrough new treatments. He also provided some insight into recent tie-ups with Denmark’s...

4 days, 16 hours ago

2 min read